Simulations Plus, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended November 30, 2017
January 09, 2018 at 09:01 pm
Share
Simulations Plus, Inc. reported unaudited consolidated earnings results for the first quarter ended November 30, 2017. For the quarter, the company reported net revenues of $7,068,782 against $5,417,933 a year ago. Income from operations was $2,563,843 against $1,928,097 a year ago. Income before provision for income taxes was $2,517,005 against $1,967,480 a year ago. Net income was $1,716,006 or $0.10 per basic and diluted share against $1,361,565 or $0.08 per basic and diluted share a year ago.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
SIMULATIONS PLUS, INC. 
